BE896822A - Procede de production d'une endotoxine detoxifiee raffinee. - Google Patents

Procede de production d'une endotoxine detoxifiee raffinee.

Info

Publication number
BE896822A
BE896822A BE0/210831A BE210831A BE896822A BE 896822 A BE896822 A BE 896822A BE 0/210831 A BE0/210831 A BE 0/210831A BE 210831 A BE210831 A BE 210831A BE 896822 A BE896822 A BE 896822A
Authority
BE
Belgium
Prior art keywords
producing
detoxified endotoxin
refined detoxified
refined
endotoxin
Prior art date
Application number
BE0/210831A
Other languages
English (en)
Inventor
E E Ribi
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of BE896822A publication Critical patent/BE896822A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
BE0/210831A 1982-05-26 1983-05-25 Procede de production d'une endotoxine detoxifiee raffinee. BE896822A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/382,404 US4436727A (en) 1982-05-26 1982-05-26 Refined detoxified endotoxin product

Publications (1)

Publication Number Publication Date
BE896822A true BE896822A (fr) 1983-09-16

Family

ID=23508804

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/210831A BE896822A (fr) 1982-05-26 1983-05-25 Procede de production d'une endotoxine detoxifiee raffinee.

Country Status (21)

Country Link
US (1) US4436727A (fr)
JP (2) JPS58216121A (fr)
KR (1) KR870000842B1 (fr)
AT (1) AT386337B (fr)
AU (1) AU556532B2 (fr)
BE (1) BE896822A (fr)
CA (1) CA1185899A (fr)
CH (1) CH661526A5 (fr)
DE (1) DE3318569A1 (fr)
DK (1) DK159275C (fr)
FI (1) FI76494C (fr)
FR (1) FR2527613B1 (fr)
GB (1) GB2122204B (fr)
HU (1) HU190491B (fr)
IL (1) IL68713A (fr)
IN (1) IN156144B (fr)
IT (1) IT1164242B (fr)
NL (1) NL194865C (fr)
NO (1) NO154864C (fr)
NZ (1) NZ204298A (fr)
SE (1) SE462017B (fr)

Families Citing this family (277)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
CA1225592A (fr) * 1983-08-26 1987-08-18 Ribi Immunochem Research Inc. Endotoxine detoxifiee raffinee
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
JPS61151157A (ja) * 1984-12-25 1986-07-09 Seiko Instr & Electronics Ltd タンパク質を加水分解する方法
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US4845036A (en) * 1987-02-03 1989-07-04 The United States Of America As Represented By The Department Of Health And Human Services Process for isolation of the B oligomer of pertussis toxin
JPH01141942U (fr) * 1988-03-24 1989-09-28
JPH01180041U (fr) * 1988-06-09 1989-12-25
US5416070A (en) * 1988-07-08 1995-05-16 Immunotherapeutics, Inc. Composition for macrophage activation
US4950645A (en) * 1988-07-08 1990-08-21 Immunotherapeutics, Inc. Composition for macrophage activation
AU4338189A (en) * 1988-09-23 1990-04-18 University Of Southern California Immunotherapy vaccine for melanoma tumors
JPH02124341U (fr) * 1989-03-24 1990-10-12
US5286718A (en) * 1991-12-31 1994-02-15 Ribi Immunochem Research, Inc. Method and composition for ameliorating tissue damage due to ischemia and reperfusion
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US5762943A (en) * 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
CN1253551C (zh) * 1997-09-10 2006-04-26 维昂药品公司 减毒的遗传修饰肿瘤靶向细菌
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
NZ508013A (en) * 1998-05-07 2003-08-29 Corixa Corp Adjuvant composition for use with an antigen in a vaccine composition
US6375952B1 (en) 1998-08-07 2002-04-23 University Of Washington Immunological herpes simplex virus antigens and methods for use thereof
US6013640A (en) 1998-08-21 2000-01-11 Ribi Immunochem Research, Inc. Phosphoglycolipid and methods for its use
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
JP2002531129A (ja) 1998-12-08 2002-09-24 コリクサ コーポレイション クラミジア感染の処置および診断のための化合物および方法
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7083796B2 (en) 2000-06-20 2006-08-01 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
AU4057300A (en) * 1999-03-30 2000-10-16 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinacious compounds
EA005140B1 (ru) 1999-04-02 2004-12-30 Корикса Корпорейшн Соединения и способы для лечения и диагностики рака легкого
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
GB9919468D0 (en) 1999-08-17 1999-10-20 Smithkline Beecham Biolog Vaccine
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
EP1229931A4 (fr) * 1999-10-07 2003-05-28 Corixa Corp Proteines hybrides de mycobacterium tuberculosis
CA2388337C (fr) 1999-10-22 2013-01-08 Aventis Pasteur Limited Procede visant a provoquer et/ou stimuler une reponse immunitaire aux antigenes tumoraux
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
IL151097A0 (en) 2000-02-23 2003-04-10 Smithkline Beecham Biolog Tumour-specific animal proteins
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US6699846B2 (en) 2000-03-17 2004-03-02 Corixa Corporation Mono- and disaccharides for the treatment of nitric oxide related disorders
WO2001081379A2 (fr) 2000-04-21 2001-11-01 Corixa Corporation Composes et procedes pour le traitement et le diagnostic d'une infection a chlamydia
DK1282702T3 (da) 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
HU230847B1 (en) 2000-05-19 2018-08-28 Corixa Corp Prophylactic and therapeutic treatment of infectious and other diseases with mono and disaccharide-based compounds
US20030139356A1 (en) * 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
AR029540A1 (es) 2000-06-28 2003-07-02 Corixa Corp COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
SI2266603T1 (sl) 2000-10-18 2012-12-31 Glaxosmithkline Biologicals S.A. Tumorska cepiva
EP2281573A3 (fr) 2001-02-23 2011-12-07 GlaxoSmithKline Biologicals s.a. Formulations de vaccins contre la grippe dispositif pour administration intradermique
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
JP2005504513A (ja) 2001-05-09 2005-02-17 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
WO2003005952A2 (fr) 2001-07-10 2003-01-23 Corixa Corporation Compositions et procedes destines a l'administration de proteines et d'adjuvants encapsules dans des microspheres
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
MXPA04002631A (es) * 2001-09-20 2004-07-08 Glaxo Group Ltd Vacunas de adn optimizadas por codon gag-vih.
DK2224012T3 (da) 2001-12-17 2013-05-13 Corixa Corp Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
US7026465B2 (en) * 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
AU2003213640A1 (en) * 2002-02-28 2003-09-16 Corixa Corporation Methods of modulating dendritic cells using adjuvants
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
ES2456066T3 (es) 2002-07-08 2014-04-21 Corixa Corporation Procesos para la producción de fosfato de aminoalquil glucosaminida e inmunoefectores disacáridos, e intermedios para ello
KR20120068769A (ko) 2002-07-15 2012-06-27 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
DK1523582T3 (da) 2002-07-18 2009-03-02 Univ Washington Hurtig, effektiv rensning af HSV-specifikke T-lymfocytter samt HSV-antigener identificeret derved
AU2003285932A1 (en) 2002-10-23 2004-05-13 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
CN101863930A (zh) 2003-01-06 2010-10-20 科里克萨有限公司 一些氨烷基氨基葡糖苷磷酸酯化合物和它们的用途
WO2005021033A2 (fr) 2003-09-02 2005-03-10 Glaxosmithkline Biologicals S.A. Vaccin
EP1713900A4 (fr) * 2004-01-27 2009-06-17 Compugen Ltd Procedes et systemes pour l'annotation de sequences de biomolecules
US8409590B2 (en) * 2004-02-11 2013-04-02 Ligocyte Pharmaceuticals, Inc. Anthrax antigens and methods of use
EP2497831B1 (fr) 2004-05-25 2014-07-16 Oregon Health and Science University Vaccin contre la Tuberculosis utilisant des vecteurs de vaccin à base de HCMV
EP2269638A3 (fr) 2004-05-28 2012-06-13 GlaxoSmithKline Biologicals S.A. Compositions de vaccin comprenant des virosomes et un adjuvant à base de saponine
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
CA2587084C (fr) 2004-10-08 2019-07-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation de la valeur adaptative reproductive au moyen de codons synonymes employes moins frequemment
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
AR054020A1 (es) 2005-03-23 2007-05-30 Glaxosmithkline Biolog Sa Nuevo uso
WO2006104890A2 (fr) 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccins destines a lutter contre une infection a chlamydia
DK2457926T3 (da) 2005-04-29 2015-01-05 Glaxosmithkline Biolog Sa Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US9259463B2 (en) 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
US8128921B2 (en) * 2006-07-11 2012-03-06 University Of Connecticut Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
US8153116B2 (en) 2006-07-11 2012-04-10 University Of Connecticut Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2068918T5 (pl) 2006-09-26 2024-12-02 Access To Advanced Health Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
WO2008059307A2 (fr) * 2006-11-16 2008-05-22 Om Pharma Bêta 1,6 glucosamine disaccharides fonctionnalisés et leur procédé de préparation
BRPI0809926B8 (pt) * 2007-04-04 2021-05-25 Infectious Disease Res Inst composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
DK2170384T3 (en) 2007-07-02 2016-07-25 Etubics Corp METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
EA017887B1 (ru) * 2007-08-02 2013-03-29 Байондвакс Фармасьютикалз Лтд. Полимерные мультиэпитопные вакцины против гриппа
KR20100068390A (ko) 2007-08-13 2010-06-23 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
US20090215710A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Carbohydrate based toll-like receptor (tlr) antagonists
US20090215908A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Toll like receptor (tlr) signaling antagonist
CN101888856B (zh) 2007-11-07 2014-08-27 塞尔德克斯医疗公司 结合人树突和上皮细胞205(dec-205)的抗体
CA2744739A1 (fr) 2007-12-03 2009-06-11 President And Fellows Of Harvard College Antigenes de chlamydia
JP5711972B2 (ja) 2007-12-24 2015-05-07 アイディー バイオメディカル コーポレイション オブ ケベック 組換えｒｓｖ抗原
AU2009208607B2 (en) * 2008-01-31 2013-08-01 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
WO2009143524A2 (fr) 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Vaccins à nanoémulsion
CA2735724C (fr) 2008-06-19 2018-07-24 Variation Biotechnologies Inc. Compositions et procedes pour le traitement de la grippe
US20110177117A1 (en) * 2008-07-18 2011-07-21 Normand Blais Chimeric respiratory syncytial virus polypeptide antigens
CN102223876A (zh) 2008-09-26 2011-10-19 纳米生物公司 纳米乳剂治疗性组合物及其使用方法
BRPI0922132A2 (pt) 2008-12-03 2018-10-23 Protea Vaccine Tech Ltd fragmentos glutamil trna sintetase (gts).
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
PE20110992A1 (es) 2009-02-17 2012-02-12 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende un antigeno del virus del dengue
US20110097418A1 (en) * 2009-05-29 2011-04-28 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
CA2764374C (fr) 2009-06-05 2019-11-19 Infectious Disease Research Institute Adjuvants lipidiques synthetiques a base de glucopyranosyle
CA2765511C (fr) 2009-06-16 2015-05-12 The Regents Of The University Of Michigan Vaccins en nano-emulsion
HUE028085T2 (en) 2009-06-24 2016-11-28 Glaxosmithkline Biologicals Sa Recombinant RSV antigens
EP2445527A2 (fr) 2009-06-24 2012-05-02 ID Biomedical Corporation of Quebec Vaccin
CA2803282C (fr) 2009-07-06 2018-05-01 David E. Anderson Procedes pour preparer des vesicules et formulations produites a partir de ces procedes
JP5854559B2 (ja) 2009-07-06 2016-02-09 ヴァリエーション バイオテクノロジーズ インコーポレイテッド 小胞を調製する方法及びこれから製造される製剤
CA2768186A1 (fr) 2009-07-15 2011-01-20 Novartis Ag Compositions a base de proteine f du vrs et procedes de fabrication associes
JP2013505022A (ja) 2009-09-16 2013-02-14 バクサート インコーポレーティッド Ｈ１ｎ１感染を予防するための免疫戦略の方法
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
WO2011067758A2 (fr) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Fragments immunogènes et multimères pour protéines de streptococcus pneumoniae
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
EA201690310A1 (ru) 2010-04-13 2016-12-30 Селлдекс Терапьютикс Инк. Антитела, связывающие cd27 человека, и их применение
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
WO2012006367A2 (fr) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions et méthodes pour traiter la grippe
BR112013004582A2 (pt) 2010-09-27 2016-09-06 Crucell Holland Bv método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
EP2627352B1 (fr) 2010-10-15 2017-05-10 GlaxoSmithKline Biologicals S.A. Antigène gb de cytomégalovirus
US20130345079A1 (en) 2010-10-27 2013-12-26 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
EP2637687B1 (fr) 2010-11-08 2021-01-06 Infectious Disease Research Institute Vaccins comprenant des polypeptides d'hydrolase nucléosidique et de stérol 24-c-méthyltransférase (smt) non spécifiques destinés à traiter et à diagnostiquer la leishmaniose
CN106822883A (zh) 2010-12-14 2017-06-13 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
BR112013018074A2 (pt) 2011-01-13 2020-12-01 Variation Biotechnologies, Inc. métodos para a preparação de vesículas e formulações produzidas a partir dessas
WO2012114323A1 (fr) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Polypeptides multimères multi-épitopes utilisés dans des vaccins contre la grippe saisonnière et pandémique
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
CA2835644C (fr) 2011-05-13 2021-06-15 Novartis Ag Antigenes de pre-fusion f du vrs
CA2837651A1 (fr) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions et methodes pour la therapie et le diagnostic du cancer
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
PL2758432T3 (pl) 2011-09-16 2019-08-30 Ucb Biopharma Sprl Przeciwciała neutralizujące przeciw głównym egzotoksynom tcda i tcdb z clostridium difficile
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
GB201119999D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP2806894A4 (fr) 2012-01-27 2015-11-04 Variation Biotechnologies Inc Procédés et compositions pour agents thérapeutiques
ES2729967T3 (es) 2012-02-07 2019-11-07 Infectious Disease Res Inst Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
WO2013139744A1 (fr) 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Procédé de vaccination contre le papillomavirus humain
EP3492095A1 (fr) 2012-04-01 2019-06-05 Technion Research & Development Foundation Limited Peptides d'inducteur de métalloprotéinase de matrice extracellulaire (emmprin) et anticorps de liaison
EP2666785A1 (fr) 2012-05-23 2013-11-27 Affiris AG Vaccins basés sur la protéine complément C5a
HUE065746T2 (hu) 2012-08-03 2024-06-28 Access To Advanced Health Inst Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
EP2703483A1 (fr) 2012-08-29 2014-03-05 Affiris AG Vaccin à base de PCSK9
WO2014043189A1 (fr) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Virus de l'herpès déficients pour la réplication conditionnelle et leur utilisation dans des vaccins
WO2014086787A1 (fr) 2012-12-05 2014-06-12 Glaxosmithkline Biologicals S.A. Composition immunogène
AU2013371454B2 (en) 2013-01-02 2019-01-03 Indaptus Therapeutics, Inc. Compositions and methods for treatment of cancer using bacteria
US11576958B2 (en) 2013-02-07 2023-02-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
EP2970398B1 (fr) 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Protéines f de rsv pré-fusion et leur utilisation
BE1022174B1 (fr) 2013-03-15 2016-02-24 Glaxosmithkline Biologicals S.A. Vaccin
EP2978447B1 (fr) 2013-03-28 2019-05-08 Infectious Disease Research Institute Vaccins comprenant des polypeptides de leishmania pour le traitement et le diagnostic de la leishmaniose
ES3020582T3 (en) 2013-07-26 2025-05-23 Inst Nat Sante Rech Med Methods and pharmaceutical compositions for the treatment of bacterial infections
MX2016001695A (es) 2013-08-05 2016-05-02 Glaxosmithkline Biolog Sa Composiciones inmunogenas de combinacion.
BR112016006122B1 (pt) 2013-09-19 2023-11-14 Novavax, Inc COMPOSIÇÃO IMUNOGÊNICA COMPREENDENDO UMA NANOPARTÍCULA DO CORONAVÍRUS DA SÍNDROME RESPIRATÓRIA DO ORIENTE MÉDIO (MERS-CoV)
KR101977449B1 (ko) 2013-11-01 2019-05-10 유니버시티에트 이 오슬로 알부민 변이체 및 이의 용도
DK3069138T3 (en) 2013-11-15 2019-04-08 Univ Oslo Hf CTL PEPTID EPITOPES AND ANTIGEN-SPECIFIC T-CELLS, METHODS OF RECOGNITION THEREOF, AND APPLICATIONS THEREOF
WO2015092710A1 (fr) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Administration simultanée controlatérale de vaccins
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
DK3107568T3 (da) 2014-02-20 2024-06-03 Vaxart Inc Formuleringer til indgivelse til tyndtarmen
JP6550072B2 (ja) 2014-04-03 2019-07-24 バイオンドバックス ファーマシューティカルズ リミテッド 多量体マルチエピトープインフルエンザポリペプチドの組成物及びそれらの生成
WO2015179270A2 (fr) 2014-05-19 2015-11-26 Board Of Regents, The University Of Texas System Plate-forme combinatoire pour la présentation d'adjuvants et d'antigènes de surface
MX384992B (es) 2014-06-13 2025-03-14 Glaxosmithkline Biologicals Sa Combinaciones inmunógenas.
BE1022949B1 (fr) 2014-06-25 2016-10-21 Glaxosmithkline Biologicals S.A. Composition immunogene
US10759836B2 (en) 2014-07-18 2020-09-01 University Of Washington Cancer vaccine compositions and methods of use thereof
EP4112076A1 (fr) 2014-10-10 2023-01-04 The Regents of The University of Michigan Compositions de nanoémulsions permettant de prévenir, de supprimer ou d'éliminer une maladie allergique et inflammatoire
WO2016097865A1 (fr) 2014-12-19 2016-06-23 Regenesance B.V. Anticorps qui se lient au c6 humain et utilisations de ceux-ci
CN107406857B (zh) 2015-01-09 2021-06-29 埃图比克斯公司 用于联合免疫治疗的方法和组合物
CN107530416A (zh) 2015-03-05 2018-01-02 西北大学 非神经侵染的病毒及其用途
WO2016145085A2 (fr) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Agonistes cd27
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2016180852A1 (fr) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de préparation de cellules t spécifiques de l'antigène à partir d'un échantillon de sang de cordon ombilical
CA2986961C (fr) 2015-05-26 2023-07-25 Ohio State Innovation Foundation Strategie vaccinale a base de nanoparticules contre le virus de la grippe porcine
EA201792512A1 (ru) 2015-06-12 2018-06-29 Вэксарт, Инк. Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
EP3359651A1 (fr) 2015-10-05 2018-08-15 THE UNITED STATES OF AMERICA, represented by the S Souche de rotavirus humain g9p[6]et utilisation comme vaccin
CA3016457A1 (fr) 2016-03-02 2017-09-08 The Board Of Regents Of The University Of Texas System Nanovaccin activant sting pour l'immunotherapie
WO2017158421A1 (fr) 2016-03-14 2017-09-21 University Of Oslo Immunoglobulines anti-virales synthétiques
CA3011887C (fr) 2016-03-14 2024-10-29 Universitetet I Oslo Immunoglobulines genetiquement transformees ayant une liaison a fcrn alteree
US12297266B2 (en) 2016-04-18 2025-05-13 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
MX2018014086A (es) 2016-05-16 2019-09-18 Infectious Disease Res Inst Formulacion que contiene agonista tlr y metodos de uso.
WO2017200957A1 (fr) 2016-05-16 2017-11-23 Infectious Disease Research Institute Liposomes pégylés et procédés d'utilisation
JP2019521095A (ja) 2016-05-21 2019-07-25 インフェクシャス ディズィーズ リサーチ インスティチュート 二次性結核および非結核性マイコバクテリウム感染症を治療するための組成物および方法
CN109890408A (zh) 2016-05-27 2019-06-14 埃特彼塞斯公司 新表位疫苗组合物及其使用方法
KR20250008135A (ko) 2016-06-01 2025-01-14 액세스 투 어드밴스드 헬스 인스티튜트 사이징제를 함유하는 나노명반 입자
US11780924B2 (en) 2016-06-21 2023-10-10 University Of Oslo HLA binding vaccine moieties and uses thereof
CN109563481B (zh) 2016-07-13 2024-01-05 俄亥俄州创新基金会 用于优化宿主抗原呈递和宿主抗肿瘤和抗病原体免疫的平台和方法
EP3504230A1 (fr) 2016-08-23 2019-07-03 GlaxoSmithKline Biologicals SA Peptides de fusion avec des antigènes liés à des fragments courts de chaîne invariante (cd74)
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
BR112019004913B1 (pt) 2016-09-16 2022-07-12 Infectious Disease Research Institute Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra
WO2018060288A1 (fr) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions et méthodes de traitement d'une infection par hpv persistante
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
WO2018096396A1 (fr) 2016-11-22 2018-05-31 University Of Oslo Variants d'albumine et leurs utilisations
US10695424B2 (en) 2016-12-07 2020-06-30 Glaxosmithkline Biologicals S.A. Method of making a liposome composition
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
US11084850B2 (en) 2016-12-16 2021-08-10 The Pirbright Institute Recombinant prefusion RSV F proteins and uses thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
WO2018193063A2 (fr) 2017-04-19 2018-10-25 Institute For Research In Biomedicine Nouveaux vaccins contre le paludisme et anticorps se liant aux sporozoïtes de plasmodium
CN110621339A (zh) 2017-04-28 2019-12-27 葛兰素史密丝克莱恩生物有限公司 疫苗接种
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
MX2019015076A (es) 2017-06-15 2020-08-03 Infectious Disease Res Inst Portadores lípidos nanoestructurados y emulsiones estables y usos de los mismos.
EP3638301A1 (fr) 2017-06-16 2020-04-22 GlaxoSmithKline Biologicals S.A. Méthode de traitement
US11123415B2 (en) 2017-08-16 2021-09-21 Ohio State Innovation Foundation Nanoparticle compositions for Salmonella vaccines
EP3678698A1 (fr) 2017-09-07 2020-07-15 University Of Oslo Molécules de vaccin
EP3678699A1 (fr) 2017-09-07 2020-07-15 University Of Oslo Molécules vaccinales
WO2019051149A1 (fr) 2017-09-08 2019-03-14 Infectious Disease Research Institute Formulations liposomales comprenant de la saponine et procédés d'utilisation
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
EP3743102A1 (fr) 2018-01-26 2020-12-02 Nantcell, Inc. Compositions et méthodes de polythérapie par vaccin anticancéreux et adjuvant immunologique
WO2019175147A1 (fr) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccins contre des infections intra-abdominales
CA3097369A1 (fr) 2018-04-17 2019-10-24 Celldex Therapeutics, Inc. Anticorps anti-cd27 et anti-pd-l1 et constructions bispecifiques
EP3807298A1 (fr) 2018-06-12 2021-04-21 GlaxoSmithKline Biologicals S.A. Polynucléotides et polypeptides d'adénovirus
EP3581201A1 (fr) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 polypeptides et leurs utilisations
CN112566654A (zh) 2018-07-31 2021-03-26 葛兰素史密丝克莱恩生物有限公司 抗原纯化方法
EP3833382A1 (fr) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processus et vaccins
CN111315407B (zh) 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
EP3897846A1 (fr) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Méthodes d'induction d'une réponse immunitaire
CA3132601A1 (fr) 2019-03-05 2020-09-10 Glaxosmithkline Biologicals Sa Regime et compositions pour l'immunisation contre l'hepatite b
CA3141577A1 (fr) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition et procede de sechage par atomisation d'une emulsion de vaccin et d'adjuvant
WO2020245207A1 (fr) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Purification de saponine
US20220273789A1 (en) 2019-07-21 2022-09-01 Glaxosmithkline Biologicals Sa Therapeutic viral vaccine
WO2021014385A1 (fr) 2019-07-24 2021-01-28 Glaxosmithkline Biologicals Sa Protéines de cytomégalovirus humain modifiées
EP3777884A1 (fr) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Composition immunogène
WO2021048081A1 (fr) 2019-09-09 2021-03-18 Glaxosmithkline Biologicals Sa Compositions immunothérapeutiques
JP2022550884A (ja) 2019-10-02 2022-12-05 ヤンセン ファッシンズ アンド プリベンション ベーフェー スタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）ペプチドおよび使用方法
WO2021097347A1 (fr) 2019-11-15 2021-05-20 Infectious Disease Research Institute Agoniste de rig-i et formulation d'adjuvant pour le traitement de tumeurs
WO2021122551A1 (fr) 2019-12-19 2021-06-24 Glaxosmithkline Biologicals Sa Antigènes de s. aureus et compositions associées
EP4461744A3 (fr) 2020-01-16 2025-01-08 Janssen Pharmaceuticals, Inc. Mutant fimh, compositions le contenant et leur utilisation
US11376320B2 (en) 2020-03-05 2022-07-05 Iowa State University Research Foundation, Inc. Immunogenic and vaccine compositions against SARS-CoV-2
EP4146378A1 (fr) 2020-05-05 2023-03-15 GlaxoSmithKline Biologicals S.A. Dispositif de mélange microfluidique et procédés d'utilisation
EP4158352A1 (fr) 2020-06-01 2023-04-05 Loop Diagnostics, S.L. Méthode et trousse de détection précoce de septicémie
WO2021245611A1 (fr) 2020-06-05 2021-12-09 Glaxosmithkline Biologicals Sa Protéines modifiées de spicule de coronavirus bêta
WO2022029024A1 (fr) 2020-08-03 2022-02-10 Glaxosmithkline Biologicals Sa PROTÉINE FUSOBACTERIUM ADHÉSINE A (FadA) DE FUSOBACTERIUM NUCLEATUM TRONQUÉE ET COMPOSITIONS IMMUNOGÈNES À BASE DE CELLE-CI
WO2022051022A1 (fr) 2020-09-04 2022-03-10 Infectious Disease Research Institute Arn co-lyophilisé et support lipidique nanostructuré
JP2023553854A (ja) 2020-12-02 2023-12-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ドナー鎖補完性ｆｉｍｈ
JP2023553904A (ja) 2020-12-09 2023-12-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン
JP2024500245A (ja) 2020-12-24 2024-01-05 プラント・バイオサイエンス・リミテッド 方法および組成物
KR20250007029A (ko) 2021-01-12 2025-01-13 얀센 파마슈티칼즈, 인코포레이티드 FimH 돌연변이체, 이를 포함하는 조성물 및 이의 용도
EP4032547A1 (fr) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Fragments dérivés du hsv 1 fce pour le traitement du hsv
MX2023009456A (es) 2021-02-11 2023-08-28 Glaxosmithkline Biologicals Sa Preparacion de la vacuna contra el vph.
IL307247A (en) 2021-04-01 2023-11-01 Janssen Pharmaceuticals Inc Production of E. Coli O18 bioconjugates
CA3214853A1 (fr) 2021-04-09 2022-10-13 Celidex Therapeutics, Inc. Anticorps contre l'anticorps ilt4, anti-ilt4/pd-l1 bispecifique et ses utilisations
WO2023020992A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
WO2023020994A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
WO2023020993A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
WO2023077521A1 (fr) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Constructions bispécifiques anti-ilt4 et anti-pd-1
WO2023144665A1 (fr) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Protéines de cytomégalovirus humain modifiées
US20250207166A1 (en) 2022-03-25 2025-06-26 Plant Bioscience Limited Biosynthesis
JP2025525334A (ja) 2022-06-15 2025-08-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニンの酵素的修飾
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions
CA3266697A1 (fr) 2022-09-09 2024-03-14 Access To Advanced Health Institute Composition de vaccin immunogène incorporant une saponine
WO2024133160A1 (fr) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Compositions pour le traitement de l'hépatite b
EP4658302A1 (fr) 2023-02-02 2025-12-10 GlaxoSmithKline Biologicals S.A. Composition immunogène
KR20250167153A (ko) 2023-03-03 2025-11-28 셀덱스 쎄라퓨틱스, 인크. 항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물
KR20260015203A (ko) 2023-05-19 2026-02-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 호흡기 세포융합 바이러스 및 스트렙토코쿠스 뉴모니아에 감염에 대한 면역 반응을 유발하는 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE185031C (fr) *
DE472221C (de) * 1924-04-01 1929-02-25 Kalle & Co Akt Ges Verfahren zur Gewinnung der toxischen Komponenten aus den Aufschluessen von Bakterien
FR2393065A1 (fr) * 1977-05-31 1978-12-29 Merieux Inst Procede de separation de lipides d'endotoxines bacteriennes et notamment d'endotoxine de bordetella pertussis

Also Published As

Publication number Publication date
AU556532B2 (en) 1986-11-06
AT386337B (de) 1988-08-10
KR870000842B1 (ko) 1987-04-25
NO154864C (no) 1987-01-07
AU1461483A (en) 1983-12-01
NO831855L (no) 1983-11-28
DE3318569A1 (de) 1984-01-12
JPS6313968B2 (fr) 1988-03-29
ATA189483A (de) 1988-01-15
DK221883D0 (da) 1983-05-18
CH661526A5 (de) 1987-07-31
IL68713A0 (en) 1983-09-30
GB2122204A (en) 1984-01-11
IL68713A (en) 1986-02-28
SE8302774L (sv) 1983-11-27
FI76494B (fi) 1988-07-29
JPH042573B2 (fr) 1992-01-20
IT8321287A0 (it) 1983-05-25
CA1185899A (fr) 1985-04-23
FI831749L (fi) 1983-11-27
JPS58216121A (ja) 1983-12-15
DE3318569C2 (fr) 1987-10-29
HU190491B (en) 1986-09-29
KR840004510A (ko) 1984-10-22
DK159275C (da) 1991-02-18
GB2122204B (en) 1985-12-24
DK221883A (da) 1983-11-27
IT1164242B (it) 1987-04-08
SE8302774D0 (sv) 1983-05-18
FI831749A0 (fi) 1983-05-18
IN156144B (fr) 1985-05-25
NL8301842A (nl) 1983-12-16
NL194865B (nl) 2003-01-06
DK159275B (da) 1990-09-24
JPS6345225A (ja) 1988-02-26
FR2527613A1 (fr) 1983-12-02
SE462017B (sv) 1990-04-30
GB8313253D0 (en) 1983-06-22
NL194865C (nl) 2003-05-06
US4436727A (en) 1984-03-13
FI76494C (fi) 1988-11-10
NO154864B (no) 1986-09-29
FR2527613B1 (fr) 1987-02-27
NZ204298A (en) 1986-10-08

Similar Documents

Publication Publication Date Title
BE896822A (fr) Procede de production d'une endotoxine detoxifiee raffinee.
FR2531440B1 (fr) Procede de production d'une membrane microporeuse
FR2565229B1 (fr) Procede de production d'epichlorhydrine
BE895067A (fr) Procede de formation d'une masse refractaire
FR2553089B1 (fr) Procede pour produire de la diethylenetriamine a partir de la monoethanolamine
FR2582294B1 (fr) Procede de production d'alumine-beta
BE878902A (fr) Procede de production d'alkylene-glycols
FR2544448B1 (fr) Procede de formation d'un raccordement hydraulique
DE3361746D1 (en) Process for producing 1,9-nonanedial
FR2593175B1 (fr) Procede de production de 3-phenyl-4-cyanopyrroles.
FR2573431B1 (fr) Procede de production d'un polymere
FR2502191B1 (fr) Procede pour produire de la carboxymethylcellulose fibreuse
FR2501214B1 (fr) Procede de production de copolymere sequence de propylene
EP0119273A4 (fr) Procede de production de poix.
RO82759A (fr) Procede de preparation d'un glycoproteine a action antitumorale
FR2490975B1 (fr) Procede de production d'objets en forme
FR2527448B1 (fr) Procede de production d'interferon
BE888562A (fr) Procede de production d'une preparation enzymatique de fructosyl-transferase,
FR2573771B1 (fr) Procede de production de peroxydase
EP0152483A4 (fr) Procede de production de peptides.
FR2539757B1 (fr) Procede de production de bilirubine-oxydase
FR2477540B1 (fr) Procede de production de 5-chloro-b-trifluoromethylpyridines
FR2575468B1 (fr) Procede de production de chlorure de methanesulfonyle
FR2663941B1 (fr) Procede de production d'organosiloxanes.
FR2534585B1 (fr) Procede de production d'alkylangelicines denuees de psoralens et alkylangelicines obtenues par ce procede

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: *RIBI IMMUNOCHEM RESEARCH INC.

Effective date: 20030525